Caprock Group LLC Takes Position in Masimo Corporation $MASI

Caprock Group LLC acquired a new position in shares of Masimo Corporation (NASDAQ:MASI) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 4,244 shares of the medical equipment provider’s stock, valued at approximately $593,000.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. MAI Capital Management lifted its holdings in shares of Masimo by 176.7% during the second quarter. MAI Capital Management now owns 202 shares of the medical equipment provider’s stock worth $34,000 after buying an additional 129 shares during the last quarter. Smartleaf Asset Management LLC raised its stake in Masimo by 80.0% during the 3rd quarter. Smartleaf Asset Management LLC now owns 306 shares of the medical equipment provider’s stock valued at $44,000 after purchasing an additional 136 shares during the last quarter. Allworth Financial LP boosted its holdings in Masimo by 72.8% in the 2nd quarter. Allworth Financial LP now owns 387 shares of the medical equipment provider’s stock valued at $65,000 after purchasing an additional 163 shares during the period. Hantz Financial Services Inc. grew its position in Masimo by 792.3% in the 3rd quarter. Hantz Financial Services Inc. now owns 580 shares of the medical equipment provider’s stock worth $86,000 after purchasing an additional 515 shares during the last quarter. Finally, Quantbot Technologies LP acquired a new stake in Masimo in the 2nd quarter worth $86,000. Institutional investors and hedge funds own 85.96% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on MASI. Zacks Research downgraded Masimo from a “strong-buy” rating to a “hold” rating in a research report on Friday, October 24th. Bank of America started coverage on Masimo in a report on Monday, November 17th. They set a “neutral” rating and a $162.00 price objective on the stock. Needham & Company LLC restated a “hold” rating on shares of Masimo in a research report on Monday, December 1st. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Masimo in a research report on Thursday, January 22nd. Finally, BTIG Research lifted their price target on shares of Masimo from $198.00 to $200.00 and gave the stock a “buy” rating in a research note on Thursday, December 4th. Four research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $189.40.

Masimo Stock Performance

NASDAQ MASI opened at $130.15 on Tuesday. Masimo Corporation has a 1-year low of $125.94 and a 1-year high of $194.88. The company has a 50 day moving average of $136.28 and a 200-day moving average of $142.46. The company has a current ratio of 2.84, a quick ratio of 1.92 and a debt-to-equity ratio of 0.69. The firm has a market cap of $6.99 billion, a price-to-earnings ratio of -12.35, a PEG ratio of 1.32 and a beta of 1.26.

About Masimo

Masimo (NASDAQ: MASI) is a global medical technology company specializing in noninvasive monitoring solutions. The company’s flagship technology, Masimo SET® (Signal Extraction Technology), enhances the accuracy of pulse oximetry in challenging clinical conditions. Beyond pulse oximetry, Masimo’s portfolio extends to brain function monitoring, regional oximetry, and acoustic respiration rate monitoring, serving critical, acute, and ambulatory care settings.

In addition to its core monitoring technologies, Masimo offers a range of patient cables, sensors, and connectivity platforms designed to integrate with hospital information systems and remote monitoring applications.